NCT01605253

Eszopiclone for the Treatment of Posttraumatic Stress Disorder

Eszopiclone for the Treatment of PTSD

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Rush University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if eszopiclone relative to placebo (sugar pill) is effective and tolerable for people with posttraumatic stress disorder (PTSD)-related sleep disturbance. The investigators will also examine the impact of treatment on sleep patterns, memory recall bias, and level of inflammatory markers (cytokines). The investigators predict eszopiclone will lead to greater improvement than placebo in measures of PTSD symptoms, memory recall bias, and level of inflammatory markers.

Conditions

• Posttraumatic Stress Disorders

Interventions

Type	Name	Description
DRUG	Eszopiclone	Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
DRUG	Placebo	The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.

Timeline

• Start date: 2012-03-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2012-05-24
• Last updated: 2022-12-23
• Results posted: 2022-12-23

Locations

1 site across 1 country: United States